Breaking News

GC Biopharma Establishes mRNA Production Facility in Korea

GMP pilot plant will support the company's strategy to internalize various mRNA-related technologies.

GC Biopharma has completed the construction of an mRNA (messenger ribonucleic acid) production facility at its vaccine production plant in Hwasun, Jeollanam-do, Korea. The GMP facility will support the company’s strategy to internalize various mRNA-related technologies and capabilities.   The new facility offers production capabilities that accommodates all phases of mRNA production, reducing the contamination risk of transfer and allowing prompt production response. The pilot plan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters